Pharmacokinetic and pharmacodynamic evaluation of site-specific pegylated glucagon-like peptide-1 analogs as flexible postprandial-glucose controllers

Journal of Pharmaceutical Sciences

Volumn 98, Issue 4, 2009, Pages 1556-1567

  Chae, Su Young ^a,d   Chun, Goo Young ^a   Lee, Seulki ^b   Jin, Cheng Hao ^a   Lee, Eun Seong ^c   Lee, Kang Choon ^a   Youn, Yu Seok ^d  

^a Sungkyunkwan University   (South Korea)

^b Korea Institute of Science and Technology   (South Korea)

^c The Catholic University of Korea   (South Korea)

^d Pusan National University   (South Korea)

Author keywords

Glucagon like peptide 1; Hypoglycemic efficacy; Pegylation; Pharmacokinetics; Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; LYSINE PEGYLATED GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SYNTHESIS; GLUCOSE BLOOD LEVEL; HYPOGLYCEMIA; INSULIN LIKE ACTIVITY; KIDNEY HOMOGENATE; LIVER HOMOGENATE; MALE; METABOLISM; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET; PHARMACOLOGICAL PARAMETERS;

EID: 67449164292     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21532     Document Type: Article

References (31)

1. Deacon CF. 2004. Therapeutic strategies based on glucagon-like peptide 1. Diabetes 53:2181-2189.
2. Kieffer TJ, Habener JF. 1999. The glucagon-like peptides. Endocr Rev 20:876-913.
3. Nauck MA. 2002. Effects of glucagon-like peptide-1 (GLP-1) on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab 87:1239-1246.
4. Fehmann HC, Habener JF. 1992. Habener, Insulio- tropic hormone glucagon-like peptide 1(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells. Endocrinology 130:159-166.
5. Li Y, Hansotia T, Yusta B, Ris F, Halban PA, Drucker DJ. 2003. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem 278:471-478.
6. Xu G, Staffers DA, Habener JF, Bonner-Weir S. 1999. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 48:2270-2276.
7. Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CM, Meeran K, Choi SJ, Taylor GM, Heath MM, Lambert PD, Wilding JP, Smith DM, Ghatei MA, Herbert J, Bloom SR. 1996. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379:69-72.
8. Kieffer TJ, Mcintosh CH, Pederson RA. 1995. Ped- erson, degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136:3585-3596.
9. Hupe-Sodmann K, McGregor GP, Bridenbaugh R, Goke R, Goke B, Thole HH, Zimmermann B, Voigt K. 1995. Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7-36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides. Regul Pept 58:149-156.
10. Simonsen L, Hoist JJ, Deacon CF. 2006. Deacon, Exendin-4, but not glucagon-like peptide-1, is cleared exclusively by glomerular filtration in anaesthetized pigs. Diabetologia 49:706-712.
11. Ruiz-Grande C, Alarcon C, Alcantara A. Castilla C, Lopez Novoa JM, Villanueva-Penacarrillo ML, Valverde I. 1993. Renal catabolism of truncated glucagon-like peptide-1. Horm Metab Res 25:612-616.
12. Elbrond B, Jakobsen G, Larsen S, Agerso H, Jensen LB, Rolan P, Sturis J, Hatorp V, Zdravkovic M. 2002. Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. Diabetes Care 25:1398-1404.
13. Kim JG, Baggio LL, Bridon DP, Castaigne JP, Robitaille MF, Jette L, Benquet C, Drucker DJ. 2003. Development and characterization of a glucagon-like peptide 1-albumin conjugate: The ability to activate the glucagon-like peptide 1 receptor in vivo. Diabetes 52:751-759.
14. Baggio LL, Huang Q, Brown TJ, Drucker DJ. 2004. A recombinant human glucagon-like peptide (GLP)- 1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Diabetes 53:2492-2500.
15. Youn YS, Chae SY, Lee S, Jeon JE, Shin HG, Lee KC. 2007. Evaluation of therapeutic potentials of site-specific PEGylated glucagon-like peptide-1 isomers as a type 2 anti-diabetic treatment, insulinotropic activity, glucose-stabilizing capability, and proteolytic stability. Biochem Pharmacol 73:84-93.
16. Lee SH, Lee S, Youn YS, Na DH, Chae SY, Byun Y, Lee KC. 2005. Synthesis, characterization, and pharmacokinetic studies of PEGylated glucagon- like peptide-1. Bioconjug Chem 16:377-382.
17. Lee S, Youn YS, Lee SH, Byun Y, Lee KC. 2006. PEGylated glucagon-like peptide-1 displays preserved effects on insulin release in isolated pancreatic islets and improved biological activity in db/ db mice. Diabetologia 49:1608-1611.
18. Salhanick AI, Clairmont KB, Buckholz TM, Pellegrino CM, Ha S, Lumb KJ. 2005. Contribution of site-specific PEGylation to the dipeptidyl peptidase IV stability of glucose-dependent insulinotropic polypeptide. Bioorg Med Chem Lett 15:4114- 4117.
19. Uchio T, Baudys M, Liu F, Song SC, Kim SW. 1999. Site-specific insulin conjugates with enhanced stability and extended action profile. Adv Drug Del Rev 35:289-306.
20. 18-amine specific PEGylation, Stability, permeability, pharmacokinetic behavior and in vivo hypocalcemic efficacy. J Control Rel 114:334-342.
21. Caliceti P, Veronese FM. 2003. Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv Drug Del Rev 55:1261- 1277.
22. Jo WY, Youn YS, Lee SH, Kim BM, Kang SH, Yoo M, Choi EC, Lee KC. 2006. Long-acting interferon-α 2 a modified with a trimer-structured polyethylene glycol, preparation, in vitro bioactivity, in vivo stability and pharmacokinetics. Int J Pharm 309:87- 93.
23. Lee KC, Moon SC, Park MO, Lee JT, Na DH, Yoo SD, Lee HS, DeLuca PP. 1999. Isolation, characterization, and stability of positional isomers of mono-PEGylated salmon calcitonins. Pharm Res 16:813- 818.
24. Na DH, Youn YS, Park EJ, Lee JM, Cho OR, Lee KR, Lee SD, Yoo SD, DeLuca PP, Lee KC. 2004. Stability of PEGylated salmon calcitonin in nasal mucosa. J Pharm Sci 93:256-261.
25. Kim MJ, Kang JH, Park YG, Ryu GR, Ko SH, Jeong IK, Koh KH, Rhie DJ, Yoon SH, Hahn SJ, Kim MS, Jo YH. 2006. Exendin-4 induction of cyclin Dl expression in INS-1 beta-cells, involvement of cAMP-responsive element. J Endocrinol 188:623- 633.
26. Al-Sabah S, Donnelly D. 2003. A model for reeeptor- peptide binding at the glucagon-like peptide-1 (GLP-1) receptor through the analysis of truncated ligands and receptors. Br J Pharmacol 140:339- 346.
27. Kim S, Kim SW, Bae YH. 2005. Synthesis, bioac- tivity and specificity of glucagon-like peptide-1 (7- 37)/polymer conjugate to isolated rat islets. Biomaterials 26:3597-3606.
28. Youn YS, Na DH, Yoo SD, Song S-C, Lee KC. 2005. Carbohydrate-specifically polyethylene glycol-modified ricin A-chain with improved therapeutic potential. Int J Biochem Cell Biol 37:1525-1533.
29. Yoo SD, Jun H, Shin BS, Lee HS, Park MO, DeLuca PP, Lee KC. 2000. Pharmacokinetic disposition of polyethylene glycol-modified salmon calcitonin. Chem Pharm Bull 48:1921-1924.
30. Harris JM, Martin NE, Modi M. 2001. Pegylation, a novel process for modifying pharmacokinetics. Clin Pharmacokinet 40:539-551.
31. Harris JM, editor. 1991. Poly(ethylene glycol) chemistry, biotechnical and biomedical applications. New York, NY: Plenum Press.